Premium
MPTP‐treated senescence accelerated mice as a novel experimental model for Parkinson's disease
Author(s) -
Boldyrev A. A.,
Sorokina E.,
Kasey V.,
Bastrikiva N.,
Fedorova T.,
Stvolinsky S.
Publication year - 2002
Publication title -
journal of neurochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.75
H-Index - 229
eISSN - 1471-4159
pISSN - 0022-3042
DOI - 10.1046/j.1471-4159.81.s1.20_7.x
Subject(s) - mptp , parkinson's disease , senescence , medicine , disease , endocrinology , chemistry , neuroscience , pharmacology , psychology
Known experimental models of Parkinson's Disease (PD) are limited by nonsimultaneous expression of physiological and biochemical features. We described a novel PD model consisting of N‐methyl,4‐phenyl‐tetrahydropyridine (MPTP) treatment of Senescence Accelerated Mice (SAM) characteristic of increased level of reactive oxygen species aggravated by deficiency of antioxidant defense system. MPTP treatment was found to suppress locomotion and enhance the nonmotivated behavior (grooming); short‐term tremor and apparent rigidity were also noted. MPTP effect was accompanied with increased level of protein carbonyls and lipid hydroperoxides indicating numerous disorders in antioxidant defense system. The brain of MPTP treated animals demonstrated higher MAO B activity and low level of SOD. Brain of control animals treated with MPTP was demonstrated by unchanged MAO B and two times decreased SOD activity; behavioral alterations in these mice being less manifested than that of SAM animals. The data presented showed that MPTP treated SAM animals are perspective model for Parkinson's disease study. Acknowledgements: The work is supported by RFBR (## 99‐04‐49420; 00‐04‐48767).